Multiplex Assays Market Report 2026

The multiplex assays market size has grown strongly in recent years. It will grow from $3.88 billion in 2025 to $4.21 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rise in molecular diagnostic usage, growing demand for pcr-based testing, expansion of research activities, increased pathogen identification needs, early adoption of multiplex protein assays.

The multiplex assays market size is expected to see strong growth in the next few years. It will grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to advancements in multiplex technologies, rising clinical diagnostic adoption, increasing application in precision medicine, expanding use in forensic laboratories, growth in genetic mutation analysis demand. Major trends in the forecast period include growing adoption of multiplex pcr for pathogen detection, rising use of multiplex assays in mutation and gene analysis, increasing demand for high-throughput protein quantification, expansion of multiplex platforms in clinical diagnostics, enhanced application of multiplex assays in forensic and research studies.

The rising incidence of chronic diseases is expected to drive the growth of the global multiplex assay market. Chronic diseases are long-term conditions that progress gradually, often affecting multiple organ systems and requiring ongoing management. Aging populations contribute significantly to this trend, as advanced age increases susceptibility to chronic conditions by reducing regenerative capacity and lengthening exposure to cumulative risk factors. Multiplex assays enable simultaneous measurement of multiple biomarkers, supporting early detection, precise disease monitoring, and improved clinical decision-making for patients with chronic diseases. For instance, in April 2024, according to Allergy UK, a UK-based national charity, more than 21 million people in the UK were affected by allergies, the most commonly reported chronic health condition in 2022, and projections indicate that by 2026, half of Europe’s population will experience at least one allergy. Therefore, the increasing incidence of chronic diseases is driving the multiplex assay market.

Major companies in the multiplex assays market are developing innovative technologies such as ultrasensitive multiplexed digital PCR assays to enhance mutation detection accuracy and streamline clinical research workflows. Ultrasensitive multiplexed digital PCR assays can detect and quantify multiple low-abundance genetic variants in a single reaction, improving sensitivity while reducing sample use and testing time. For example, in January 2024, Bio-Rad Laboratories Inc., a US-based life sciences and diagnostics company, launched the ddPLEX ESR1 Mutation Detection Kit, the first ultrasensitive multiplexed digital PCR assay specifically designed to detect breast cancer mutations in clinical research. This assay simultaneously detects and quantifies seven ESR1 mutations in a single well, with analytical sensitivity down to 0.01% variant allele fraction (VAF), and can be used with circulating tumor DNA (ctDNA) from plasma or DNA from FFPE tissue samples.

In May 2025, Vizgen, Inc., a US-based provider of spatial multi-omics platforms, partnered with Hamamatsu Photonics K.K., a Japan-based technology company, to integrate multiplex immunofluorescence imaging with advanced multiplex assay chemistry. This collaboration aims to streamline spatial biology workflows by combining Vizgen’s InSituPlex multiplex assays with Hamamatsu’s MoxiePlex multiplex imaging system, providing a seamless end-to-end solution for translational and clinical biomarker research.

Major companies operating in the multiplex assays market are Seegene Inc, DiaSorin SpA, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Abcam Plc, PerkinElmer Inc, Hologic Corporation, Meso Scale Diagnostics, Merck KGaA, Roche Diagnostics India Pvt Ltd, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Johnson & Johnson, Simens Healthcare, Beckman Coulter Inc. India, Ortho Clinical Diagnostics, Sysmex Corporation, Siemens Healthineers Ukraine, TestLine Clinical Diagnostics s.r.o., Cepheid, F. Hoffmann-La Roche Ltd., Hologic, Bayer AG, Cantel Medical Corporation, Meridian Bioscience, Faizyme Laboratories, Alere Inc., Bangs Laboratories Inc, The Merck Group, Takara Bio Inc, Qiagen, Spherotech Inc, Geneaid Biotech Ltd, Rockland Immunochemicals Inc, GenScript Biotech Corporation.

North America was the largest region in the multiplex assays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiplex assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on diagnostic instruments, PCR systems, and reagent imports have increased overall operational costs in the multiplex assays market, particularly affecting hospitals, research labs, and biotechnology companies dependent on imported kits and analytical instruments. These tariffs slow adoption in lower-income regions and add constraints to supply chains. However, they also stimulate domestic manufacturing of diagnostic platforms and reagents, encouraging local innovation and reducing long-term import dependency.

The multiplex assays market research report is one of a series of new reports that provides multiplex assays market statistics, including multiplex assays industry global market size, regional shares, competitors with a multiplex assays market share, detailed multiplex assays market segments, market trends and opportunities, and any further data you may need to thrive in the multiplex assays industry. This multiplex assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multiplex assays are used to amplify multiple targets in a polymerase chain reaction (PCR) and gather additional information from minute amounts of proteins or other analytes in less time compared to conventional methods, similar to ELISA. These assays are applied in pathogen identification, mutation analysis, RNA discovery, gene discovery, relationship analysis, forensic studies, and more.

The main types of multiplex assays include nucleic acid-based multiplex assays, protein-based multiplex assays, and others. Nucleic acid-based multiplex assays detect organism-specific DNA or RNA sequences and are highly specific and sensitive, providing rapid results. Technologies used in multiplex assays include flow cytometry, luminescence, fluorescence detection, multiplex real-time PCR, and others. These assays are employed in applications such as research and development and clinical diagnostics, with end users including pharmaceutical and biotechnology companies, hospitals, research institutes, reference laboratories, and others.

The multiplex assays market consists of sales of equipment with technologies that can detect multiple genes such as flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies in multiplex assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.